Methyl-β-cyclodextrin in HL-60 parental and multidrug-resistant cancer cell lines: Effect on the cytotoxic activity and intracellular accumulation of doxorubicin

Cancer Chemotherapy and Pharmacology

Volumn 40, Issue 6, 1997, Pages 489-494

  Grosse, Pierre Yves ^a,b   Bressolle, Françoise ^b   Pinguet, Frédéric ^a  

^a CENTRE VAL D AURELLE   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

Cytotoxic activity; Doxorubicin; HL 60; Intracellular concentration; Methyl cyclodextrin; Parental and multidrug resistant human cancer cell lines

Indexed keywords

DOXORUBICIN; HEPTAKIS(2,6 O DIMETHYL) BETA CYCLODEXTRIN;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSPORT; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG TISSUE LEVEL; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; BETA-CYCLODEXTRINS; CELL DIVISION; CYCLODEXTRINS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HL-60 CELLS; HUMANS;

EID: 0030763761     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050692     Document Type: Article

References (26)

1. Allegre M, Deratani A (1994) Cyclodextrin uses: from concept to industrial reality. Agro-food Ind Hi-Tech 1: 9
2. Alley MC, Scudiero DA, Monks A (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48: 589
3. Bekers O, Beijnen JH, Otagiri M, Bult A, Underberg WJ (1990) Inclusion complexation of doxorubicin and daunorubicin with cyclodextrins. J Pharm Biomed Anal 8: 671
4. Bellringer ME, Smith TG, Read R, Gopinath C, Olivier P (1995) β-Cyclodextrin: 52-week toxicity studies in the rat and dog. Food Chem Tox 33: 367
5. Bielack SS, Erttmann R, Winkler K, Landbeck G (1989) Doxorubicin: effect of different schedules on toxicity and antitumor activity. Eur J Cancer Clin Oncol 25: 873
6. Castelli F, Puglisi G, Pignatello R, Gurrieri S (1989) Calorimetric studies of the interaction of 4-biphenylacetic acid and its β-cyclodextrin inclusion compound with lipid model membrane. Int J Pharm 52: 115
7. Clarke R, Van De Berg HW, Nelson J, Mulphy RF (1987) Pharmacological and suprapharmacological concentrations of both 17β estradiol (E2) and tamoxifen (TAM) reduce the membrane fluidity of MCF-7 and MDA-MB-436 human breast cancer cells. Biochem Soc Trans 15: 243
8. Cucinotta V, Mangano A, Nobile G, Santoro AM, Vecchio G (1993) New platinum(II) complexes of β-cyclodextrin diamine derivatives and their antitumor activity. J Inorg Biochem 52: 183
9. Cuvier C, Roblot-Treupel L, Millot JM, Lizard G, Chevillard S, Manfait M, Couvreur P, Poupon MF (1992) Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Biochem Pharmacol 44: 509
10. Frijlink HW, Franssen EJF, Eissens AC, Oosting R, Lerk CF, Meijer DKF (1991) The effect of cyclodextrins on the disposition of intravenously injected drugs in the rat. Pharm Res 8: 380
11. Gibaud S, Andreux JP, Weingarten C, Renard M, Couvreur P (1994) Increased bone marrow toxicity of doxorubicin bound to nanoparticules. Eur J Cancer 30: 820
12. Heo DS, Park JG, Hata K, Day R, Heberman RB, Whiteside TE (1990) Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity. Cancer Res 30: 3681
13. Hiruyama F, Uekama K (1987) Cyclodextrins and their industrial uses. Editions Duchêne Editions de Santé. Paris, p 131
14. Leibovici J, Klein O, Wollman Y, Donin N, Mahlin T, Shinitzky M (1996) Cell membrane fluidity and adriamycin retention in a tumor progression model of AKR lymphoma. Biochim Biophys Acta 1281: 182
15. Müller BW, Albers A (1991) Effect of hygrotropic substances on the complexation of sparingly soluble drugs with cyclodextrin derivatives and the influence of the cyclodextrin complexation of the pharmacokinetics of the drugs. J Pharm Sci 80: 599
16. Muggia FM, Green MD (1991) New anthracycline antitumor antibiotics. CRC Crit Rev Oncol Hematol 11: 43
17. Muller C, Chatelut E, Gualano V, De Forni M, Huguet F, Attal M, Canal P, Laurent G (1993) Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. Cancer Chemother Pharmacol 32: 379
18. Myles AM, Barlow DJ, France G, Lawrence MJ (1994) Analysis and modelling of the structures of beta-cyclodextrin complexes. Biochim Biophys Acta 1199: 27
19. Oudard S, Thierry A, Jorgensen TJ, Rahman A (1991) Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes. Cancer Chemother Pharmacol 28: 259
20. Scambia G, Ranaletti FO, Benedetti Panici P, De Vincenzo R, Bonnano G, Ferrandina F, Piantelli M, Bussa S, Rumi C, Cianfriglia M, Mancuso M (1994) Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 34: 459
21. Skehan P, Storeng R, Seuderio G (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107
22. Szetlji J (1988) Cyclodextrin technology. Kluwer Dordrecht
23. Szetlji J (1994) Medicinal applications of cyclodextrins. Med Res Rev 14: 353
24. Szejtji J, Cserhàti T, Szögyi M (1986) Interactions between cyclodextrins and cell-membrane phospholipids. Carbohydr Polymers 6: 35
25. Tanaka H, Kominato K, Yamamoto R, Yoshioka T, Nishida H, Tone H, Okamoto R (1994) Synthesis of doxorubicin-cyclodextrin conjugates. J Antibiot (Tokyo) 47: 1025
26. Teicher BA, Sotomayor EA, Huang ZD, Ara G, Holden S, Khandekar V, dien YN (1993) β-Cyclodextrin tetradecasulfate/tetrahydrocortisol ± minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma. Cancer Chemother Pharmacol 33: 229